Nasdaq · Technology
GoodRx Holdings, Inc. (GDRX)
As-reported financials and recent SEC filings for GoodRx Holdings, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$796.9M
Net income
$30.4M
Net margin
3.8%
Diluted EPS
$0.09
ROE
4.9%
P/E (TTM)
46.7×
Market cap
$948.3M
Debt / equity
0.8×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $796.9M | $792.3M | $750.3M | $766.6M | $745.4M |
| Gross profit | — | — | — | — | — |
| Operating income | $87.5M | $65.8M | $-27.0M | $1.7M | $13.4M |
| Net income | $30.4M | $16.4M | $-8.9M | $-32.8M | $-25.3M |
| Diluted EPS | $0.09 | $0.04 | $-0.02 | $-0.08 | $-0.06 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-18
View on EDGAR →42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →42026-06-15
View on EDGAR →Go deeper on GDRX
Search GoodRx Holdings, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.